Last updated: September 4, 2026
Chlorothiazide sodium is an established thiazide diuretic supplied primarily as a sterile injectable powder for reconstitution. Its commercial opportunity is limited by generic competition and the absence of meaningful regulatory exclusivity, but hospital-use improvements remain possible through ready-to-use presentations, pediatric dosing formats, stability enhancements, and supply-chain differentiation. The principal technical challenge is developing a stable aqueous formulation at the alkaline pH required for chlorothiazide sodium solubility.
What is the current pharmaceutical formulation of chlorothiazide sodium?
Chlorothiazide sodium injection is an intravenous dosage form containing chlorothiazide sodium equivalent to 500 mg of chlorothiazide per vial. The product is supplied as a sterile powder that is reconstituted before administration. The formulation is generally preservative-free and does not rely on a complex excipient system. FDA labeling directs reconstitution with Sterile Water for Injection and identifies alkaline solution conditions and compatibility constraints associated with the product.[1]
| Attribute |
Chlorothiazide sodium injection |
| Active ingredient |
Chlorothiazide sodium |
| Therapeutic class |
Thiazide diuretic |
| Typical strength |
500 mg chlorothiazide equivalent per vial |
| Route |
Intravenous after reconstitution |
| Dosage form |
Sterile powder for solution |
| Common clinical setting |
Hospital and acute-care use |
| Preservatives |
Generally absent from the lyophilized vial |
| Reconstitution vehicle |
Sterile Water for Injection |
| Primary formulation issue |
Aqueous stability, pH control, precipitation and compatibility |
| Regulatory pathway for a conventional generic |
ANDA, if pharmaceutical equivalence and bioequivalence requirements are met |
The injectable product is used when oral administration is impractical or when a diuretic effect is required in an acute-care setting. It can be used alone or in combination with loop diuretics under clinical supervision.
What excipients are used in chlorothiazide sodium injection?
The current injectable format uses a minimal-excipient strategy. The commercial value of the formulation is tied less to excipient complexity than to sterile manufacturing, reconstitution performance, container closure integrity and control of the drug’s solution chemistry.
Why is a low-excipient formulation commercially attractive?
A low-excipient formulation offers several advantages:
- Lower risk of excipient-related adverse reactions.
- Simpler regulatory comparison with the reference product.
- Reduced extractables, leachables and particulate burden.
- Easier compatibility assessment for hospital use.
- Lower formulation-development cost.
- Less risk that an excipient will alter pH, solubility or degradation.
For an established injectable drug, excipient reduction can support a conventional ANDA strategy if the proposed product matches the reference product in qualitative and quantitative composition or satisfies FDA requirements for a permissible difference.
Which excipients could improve the formulation?
Potential excipients fall into four categories.
| Excipient category |
Potential role |
Key risk |
| Buffering agents |
Maintain the pH required for solubility and stability |
Precipitation, degradation or incompatibility |
| Tonicity agents |
Improve osmolality in ready-to-use products |
Increased sodium or osmotic load |
| Solubilizers |
Improve aqueous solubility |
Toxicity, hypersensitivity and regulatory complexity |
| Bulking agents |
Support lyophilized cake structure |
Residual moisture and reconstitution effects |
A phosphate, citrate or acetate buffer would require particular caution. Chlorothiazide sodium is a weakly soluble compound whose behavior depends on alkaline conditions. A buffer that shifts the solution toward a lower pH could reduce solubility and cause precipitation. The development objective should therefore be pH control without introducing a high buffer capacity that creates incompatibility with commonly used infusion fluids.
Mannitol or another bulking agent could improve the appearance and mechanical strength of a lyophilized cake. Its inclusion would need to be justified against the commercial advantages of a minimal formulation. If the existing product already produces an acceptable cake and reconstitutes rapidly, adding a bulking agent may increase regulatory and manufacturing complexity without creating a meaningful clinical benefit.
What formulation strategies could create commercial differentiation?
The strongest opportunities involve administration convenience rather than a new pharmacologic mechanism.
Ready-to-use chlorothiazide sodium injection
A ready-to-use vial, syringe or small-volume bag could eliminate bedside reconstitution. This could reduce pharmacy preparation time, lower dosing errors and improve administration in intensive-care settings.
The key development requirements are:
- Long-term chemical stability in the selected vehicle.
- Control of precipitation across the labeled storage range.
- Container compatibility.
- Low particulate generation.
- Sterility assurance throughout the shelf life.
- Compatibility with common IV administration systems.
- A clinically useful concentration that avoids excessive injection volume.
The commercial advantage would be strongest where hospitals pay for pharmacy labor, preparation efficiency and medication-safety improvements. A ready-to-use product would face a higher development burden than a conventional lyophilized vial because the formulation would need to remain stable in aqueous solution for the full labeled shelf life.
Improved lyophilized vial
A reformulated powder could compete without solving the more difficult problem of long-term aqueous stability. Potential improvements include:
- Faster reconstitution.
- Smaller vial fill volume.
- Reduced foaming.
- More robust cake structure.
- Clearer labeling of the final concentration.
- Reduced residual moisture.
- Lower risk of incomplete dissolution.
This strategy is likely to fit a conventional generic or line-extension model more closely than an aqueous ready-to-use product.
Pediatric and neonatal dosing presentation
Chlorothiazide is used in pediatric and neonatal fluid-management settings, where dose accuracy and low administration volume have commercial importance. A lower-concentration presentation, unit-dose vial or pharmacy-ready format could address problems created by diluting a high-strength adult vial.
A pediatric product would need careful control of:
- Final concentration.
- Dose-measurement accuracy.
- Preservative exposure.
- Osmolality.
- Sodium burden.
- Compatibility with enteral or parenteral delivery systems.
- Stability after dilution.
A pediatric ready-to-use product could obtain market differentiation even if the active ingredient and mechanism are generic.
Dual-chamber or on-demand reconstitution system
A dual-chamber container could separate the dry drug from the diluent until administration. This design would preserve the stability advantages of a powder while reducing preparation steps. The principal obstacles would be device development, container closure validation, human-factors testing and a more complex regulatory submission.
The opportunity is more suitable for a hospital-focused specialty manufacturer than for a low-cost generic supplier.
When does chlorothiazide sodium lose exclusivity?
Chlorothiazide sodium is an old small-molecule drug with no meaningful market exclusivity associated with the active ingredient. The commercial market is primarily generic. FDA approval and labeling information identify the product as an established drug rather than a recently introduced innovative therapy.[1,2]
What is the Orange Book status of chlorothiazide sodium?
The relevant regulatory question is product-specific. A conventional chlorothiazide sodium injection approved through an ANDA does not receive new-drug market exclusivity merely because it is a generic injectable. Any remaining patent or exclusivity issue would depend on the specific reference product, dosage form, listed patents and FDA Orange Book records.[2]
For commercial planning, the more important conclusion is that market entry is primarily constrained by:
- Sterile injectable manufacturing capacity.
- FDA inspection and approval timing.
- Drug-shortage conditions.
- Hospital contracting.
- Product reliability.
- Ability to maintain supply of sterile vials and components.
What patent protection covers chlorothiazide sodium?
The active ingredient and basic use of chlorothiazide sodium are long-established. No commercially significant composition-of-matter patent protection is expected to remain for the molecule. Potentially relevant intellectual-property areas include:
- A novel ready-to-use aqueous formulation.
- A specific pH and excipient combination.
- A stable premixed infusion.
- A dual-chamber delivery system.
- A pediatric concentration or dosing system.
- A manufacturing process that improves impurity control.
- A container closure or reconstitution device.
Any new patent claim would need to overcome the obviousness risk associated with reformulating an established injectable drug. Stronger claims would require demonstrated stability, safety, manufacturability or clinical workflow benefits that are not predictable from the prior art.
Are there Paragraph IV challenges for chlorothiazide sodium?
Paragraph IV litigation risk is likely to be limited because chlorothiazide sodium is an old generic product with multiple potential suppliers and little apparent remaining patent value. A Paragraph IV filing would be relevant only if an Orange Book-listed patent covered the specific reference product and had not expired or been disclaimed.
For a new entrant, the principal regulatory pathway would typically be an ANDA referencing the applicable listed drug, assuming the proposed product is pharmaceutically equivalent. A materially different formulation, new delivery system or novel ready-to-use product could require a 505(b)(2) application instead of a straightforward ANDA.[3]
What FDA regulatory status applies to a new chlorothiazide sodium product?
Conventional sterile powder
A sterile powder that matches the reference product in active ingredient, strength, dosage form, route and key formulation characteristics may be suitable for an ANDA. The submission would require, among other elements:
- Chemistry, manufacturing and controls information.
- Sterility and endotoxin controls.
- Container closure data.
- Stability studies.
- Reconstitution and dilution studies.
- Injectable product quality data.
- Pharmaceutical equivalence documentation.
Ready-to-use injectable
A ready-to-use aqueous product may not qualify as a simple generic if its formulation, concentration, vehicle, container or administration method differs materially from the reference product. The sponsor may need to use a 505(b)(2) pathway and provide additional safety, stability, compatibility and clinical justification.[3]
Biosimilar risk
Biosimilar risk does not apply. Chlorothiazide sodium is a synthetic small molecule, not a biologic. Competitive pressure comes from generic injectable manufacturers, not biosimilar developers.
What manufacturing and intellectual-property barriers affect market entry?
Sterile manufacturing is the main barrier. The active pharmaceutical ingredient is not the difficult part of the supply chain. The higher-risk operations include:
- Aseptic filling or sterile lyophilization.
- Sterile filtration, where applicable.
- Control of alkaline solution chemistry.
- Low-bioburden handling before sterilization.
- Vial and stopper qualification.
- Particulate control.
- Reconstitution validation.
- Batch-release testing.
- Reliable access to contract manufacturing capacity.
An injectable supplier can obtain commercial leverage through a dependable supply record. Hospitals may prefer a slightly higher-priced product if it reduces shortage exposure or pharmacy preparation workload.
Which companies are challenging the chlorothiazide sodium market?
The market is likely to contain brand-linked and generic suppliers, depending on current commercial availability and procurement contracts. Competition is based on product availability, price, shortage resilience, vial configuration and hospital distribution rather than clinical differentiation.
A new entrant would compete against:
| Competitor type |
Primary advantage |
| Established generic injectable suppliers |
Existing FDA approval, contracts and distribution |
| Brand-linked suppliers |
Recognized product identity and institutional familiarity |
| Contract manufacturers |
Flexible production and licensing capacity |
| Specialty hospital-product companies |
Focus on ready-to-use and shortage-prone injectables |
| 505(b)(2) developers |
Ability to introduce new concentrations, vehicles or devices |
No biosimilar competitors are relevant. No broad commercial licensing trend is evident for the active ingredient itself. Licensing may have value for a differentiated presentation, a sterile manufacturing platform or a hospital distribution network.
What commercial opportunities exist for chlorothiazide sodium?
The most credible opportunities are product and supply-chain opportunities.
Opportunity ranking
| Opportunity |
Commercial potential |
Development complexity |
| Reliable 500 mg lyophilized vial |
Moderate |
Low to moderate |
| Faster-reconstituting powder |
Moderate |
Moderate |
| Pediatric unit-dose presentation |
Moderate to high |
Moderate |
| Ready-to-use syringe |
High if stability is proven |
High |
| Premixed infusion bag |
High operational value |
High |
| Dual-chamber delivery system |
Moderate to high |
High |
| Novel excipient platform |
Uncertain |
High |
Revenue exposure is concentrated in institutional channels, including hospitals, intensive-care units, pediatric centers and specialty pharmacies. The total opportunity is smaller than that of high-volume antibiotics or oncology injectables, but supply interruptions can create attractive pricing and contract opportunities.
What patent litigation affects chlorothiazide sodium?
The active ingredient’s age makes major composition-of-matter litigation unlikely. Litigation risk would be more likely to arise from:
- A patent on a novel injectable formulation.
- Trade-secret disputes involving sterile manufacturing.
- Device patents covering a reconstitution system.
- Contract disputes involving hospital supply.
- ANDA litigation if a new listed formulation obtains patent protection.
No significant litigation or settlement agreement is identified in the regulatory materials cited here. A commercial diligence review should distinguish patents covering chlorothiazide sodium itself from patents covering a specific product, device or manufacturing process.
How strong is the chlorothiazide sodium patent estate?
The patent estate for the established active ingredient is weak from a market-exclusivity perspective. A new entrant is more likely to obtain defensible protection around formulation performance or delivery technology than around chlorothiazide sodium.
A strong formulation patent would need to claim a defined combination of:
- Drug concentration.
- pH range.
- Excipient identity and level.
- Storage condition.
- Degradation profile.
- Reconstitution time.
- Container configuration.
- Clinical or operational benefit.
Broad claims covering routine buffers, tonicity agents or standard lyophilization techniques would face substantial validity risk.
Key Takeaways
- Chlorothiazide sodium injection is an established sterile powder product with a minimal-excipient profile.
- The central technical issue is maintaining solubility and stability in an alkaline aqueous environment.
- A conventional 500 mg lyophilized vial is the lowest-risk development strategy.
- Ready-to-use syringes, premixed bags and pediatric unit-dose formats offer the clearest commercial differentiation.
- Biosimilar competition does not apply because chlorothiazide sodium is a synthetic small molecule.
- Patent value is more likely to arise from formulation, device or manufacturing claims than from the active ingredient.
- Sterile manufacturing capacity, reliable supply and hospital workflow benefits are stronger commercial barriers than molecule-level intellectual property.
- An ANDA is the likely route for a conventional equivalent product; a materially different ready-to-use formulation may require a 505(b)(2) application.
FAQs
Can chlorothiazide sodium injection be sold as a ready-to-use product?
Yes, but the sponsor would need to establish long-term aqueous stability, compatibility, sterility, particulate control and an appropriate regulatory pathway. The formulation must prevent precipitation and maintain potency throughout the labeled shelf life.
Is chlorothiazide sodium compatible with normal saline?
Compatibility depends on concentration, pH, storage duration, container and administration conditions. Compatibility cannot be assumed from the active ingredient alone. Product-specific studies are required before labeling a saline dilution.
Does chlorothiazide sodium have a meaningful pediatric formulation opportunity?
Yes. Pediatric and neonatal care may benefit from lower concentrations, unit-dose packaging and pharmacy-ready presentations that improve dose accuracy and reduce dilution steps.
Would a new chlorothiazide sodium formulation receive new exclusivity?
A new formulation could qualify for regulatory or patent protection only if it meets the applicable statutory requirements and contains a sufficiently distinct, non-obvious innovation. A routine change in excipients is unlikely to create durable exclusivity.
What is the most defensible commercial position for a new entrant?
The strongest position is a reliable hospital injectable with a differentiated presentation, such as a rapidly reconstituting vial, pediatric unit dose or validated ready-to-use format. Price-only competition against established generic vials is less attractive.
References
-
DailyMed. (n.d.). Chlorothiazide sodium for injection prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). https://www.fda.gov/drugs/development-resources/applications-covered-section-505b2-act
-
U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
-
U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.
